

Selected 2004 Public Offerings

2005-01-01

In 2004, we handled more than 75 public offerings and Rule 144A placements raising more than \$20 billion. In the past five years, we have served as counsel to the issuer, underwriters or agents in more than 250 public offerings and Rule 144A placements raising over \$100 billion, including more IPOs in the eastern United States—as both issuer and underwriters' counsel—than any other law firm in the country. Selected 2004 transactions are listed below:

- **Alnylam Pharmaceuticals**— Initial Public Offering of Common Stock — \$32,085,000 — Counsel to Issuer
- **Amdocs**— Rule 144A Placement of 0.50% Convertible Senior Notes due 2024 — \$450,000,000 — Counsel to Issuer
- **Barrier Therapeutics**— Initial Public Offering of Common Stock — \$75,000,000 — Counsel to Underwriters
- **Blackboard**— Initial Public Offering of Common Stock — \$88,550,000 — Counsel to Issuer
- **CapitalSource**— Rule 144A Placements of Senior Convertible Debentures due 2034 — \$555,000,000 — Counsel to Initial Purchasers
- **Casella Waste Systems**— Rule 144A Placement of 9.75% Senior Subordinated Notes due 2013 — \$51,100,000 — Counsel to Issuer
- **CB Richard Ellis Group** — Initial Public Offering and Secondary Public Offering of Common Stock — \$943,356,700 — Counsel to Selling Stockholder
- **CIT Group** — Public Offerings of Medium-Term Notes — \$12,040,000,000 — Counsel to Underwriters and Agents
- **Civica** — Initial Public Offering of Ordinary Shares — £45,000,000 — Counsel to Underwriters
- **Corporación Andina de Fomento** — Public Offerings of Floating Rate Notes — \$350,000,000 — Counsel to Underwriters
- **Critical Therapeutics** — Initial Public Offering of Common Stock — \$42,770,000 — Counsel to Issuer
- **Cubist Pharmaceuticals** — Follow-On Public Offering of Common Stock — \$119,999,040 — Counsel to Underwriters
- **EPIX Medical** — Rule 144A Placement of 3.00% Convertible Senior Notes due 2024 — \$100,000,000 — Counsel to Initial Purchasers

- **Essex** — Follow-On Public Offering of Common Stock — \$114,000,000 — Counsel to Underwriters
- **Eyetech Pharmaceuticals** — Initial Public Offering of Common Stock — \$156,975,000 — Counsel to Issuer
- **First Marblehead** — Follow-On Public Offering of Common Stock — \$270,330,388 — Counsel to Issuer
- **Gatekeeper Systems** — Initial Public Offering of Common Stock — £8,112,000 — Counsel to Issuer
- **GTx** — Initial Public Offering of Common Stock — \$78,300,000 — Counsel to Underwriters
- **John Hancock** — Initial Public Offerings of Common Stock and Preferred Stock of Closed-End Funds — \$1,221,400,000 — Counsel to Issuer
- **Idenix Pharmaceuticals** — Initial Public Offering of Common Stock — \$81,200,000 — Counsel to Issuer
- **LTX** — Follow-On Public Offering of Common Stock — \$132,825,000 — Counsel to Issuer
- **MapInfo** — Follow-On Public Offering of Common Stock — \$47,437,500 — Counsel to Issuer
- **MKS Instruments** — Follow-On Public Offering of Common Stock — \$115,316,020 — Counsel to Issuer
- **Momenta Pharmaceuticals** — Initial Public Offering of Common Stock — \$39,991,250 — Counsel to Issuer
- **NitroMed** — Follow-On Public Offering of Common Stock — \$87,553,982 — Counsel to Issuer
- **Open Solutions** — Follow-On Public Offering of Common Stock — \$90,614,328 — Counsel to Issuer
- **Pioneer** — Initial Public Offerings of Common Stock and Preferred Stock of Closed-End Funds — \$1,036,553,000 — Counsel to Issuer
- **PS Business Parks** — Follow-On Public Offerings of Preferred Stock — \$395,000,000 — Counsel to Underwriters
- **Red Hat** — Rule 144A Placement of 0.50% Convertible Senior Debentures due 2024 — \$600,000,000 — Counsel to Issuer
- **Sepracor** — Rule 144A Placement of 0% Convertible Senior Subordinated Notes due 2024 — \$500,000,000 — Counsel to Issuer
- **SS&C Technologies** — Follow-On Public Offering of Common Stock — \$100,912,500 — Counsel to Issuer
- **Timberland** — Secondary Public Offerings of Common Stock — \$399,173,389 — Counsel to Underwriters
- **Transkaryotic Therapies** — Follow-On Public Offering of Common Stock — \$90,000,000 — Counsel to Issuer
- **Vicuron Pharmaceuticals** — Follow-On Public Offering of Common Stock — \$74,502,250 — Counsel to Underwriters